PURPOSE: To evaluate contrast agent-enhanced ultrasonography (US) in the detection of untreated tumor after radio-frequency (RF) ablation of hepatic metastases. MATERIALS AND METHODS: Twenty patients with solitary colorectal liver metastases underwent percutaneous RF tumor ablation. Pre- and postablation imaging was performed with nonenhanced and enhanced color and power Doppler US and contrast-enhanced helical computed tomography (CT). Initial follow-up CT and US were performed 24 hours after ablation. The findings at US and CT were compared. RESULTS: Nonenhanced US demonstrated intratumoral signal in 15 of 20 metastases before ablation. This signal increased after contrast agent administration. Contrast-enhanced US performed 24 hours after ablation demonstrated residual foci of enhancement in three tumors, whereas no US signals were seen in any tumor on nonenhanced scans. CT demonstrated small (< 3-mm) persistent foci of residual enhancement in these three tumors and in three additional lesions that were not seen at US (US sensitivity, 50%; specificity, 100%; diagnostic agreement with CT, 85%). All six patients with evidence of residual tumor underwent repeat RF ablation. CONCLUSION: Contrast-enhanced US may depict residual tumor after RF application and thereby enable additional directed therapy. The potential reduction in treatment sessions and/or ancillary imaging procedures might increase the ease and practicality of percutaneous ablation of focal hepatic metastases.
PURPOSE: To evaluate contrast agent-enhanced ultrasonography (US) in the detection of untreated tumor after radio-frequency (RF) ablation of hepatic metastases. MATERIALS AND METHODS: Twenty patients with solitary colorectal liver metastases underwent percutaneous RF tumor ablation. Pre- and postablation imaging was performed with nonenhanced and enhanced color and power Doppler US and contrast-enhanced helical computed tomography (CT). Initial follow-up CT and US were performed 24 hours after ablation. The findings at US and CT were compared. RESULTS: Nonenhanced US demonstrated intratumoral signal in 15 of 20 metastases before ablation. This signal increased after contrast agent administration. Contrast-enhanced US performed 24 hours after ablation demonstrated residual foci of enhancement in three tumors, whereas no US signals were seen in any tumor on nonenhanced scans. CT demonstrated small (< 3-mm) persistent foci of residual enhancement in these three tumors and in three additional lesions that were not seen at US (US sensitivity, 50%; specificity, 100%; diagnostic agreement with CT, 85%). All six patients with evidence of residual tumor underwent repeat RF ablation. CONCLUSION: Contrast-enhanced US may depict residual tumor after RF application and thereby enable additional directed therapy. The potential reduction in treatment sessions and/or ancillary imaging procedures might increase the ease and practicality of percutaneous ablation of focal hepatic metastases.
Authors: D J Scott; W N Young; L M Watumull; G Lindberg; J B Fleming; J F Huth; R V Rege; D R Jeyarajah; D B Jones Journal: Surg Endosc Date: 2001-02 Impact factor: 4.584
Authors: M D Scott DJ; W N Young; L M Watumull; G Lindberg; J B Fleming; R V Rege; R J Brown; D B Jones Journal: J Gastrointest Surg Date: 2000 Nov-Dec Impact factor: 3.452
Authors: Man Zhang; Benjamin Castaneda; Jared Christensen; Wael E Saad; Kevin Bylund; Kenneth Hoyt; John G Strang; Deborah J Rubens; Kevin J Parker Journal: Med Phys Date: 2008-09 Impact factor: 4.071
Authors: Brian J Fahey; Rendon C Nelson; Stephen J Hsu; David P Bradway; Douglas M Dumont; Gregg E Trahey Journal: Ultrasound Med Biol Date: 2008-05-09 Impact factor: 2.998
Authors: Seung Kwon Kim; Hyo K Lim; Jeong-ah Ryu; Dongil Choi; Won Jae Lee; Ji Yeon Lee; Ju Hyun Lee; Yon Mi Sung; Eun Yoon Cho; Seung-Mo Hong; Jong-Sung Kim Journal: Korean J Radiol Date: 2004 Oct-Dec Impact factor: 3.500